Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Research

Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer

Authors: Yu-Wen Cao, Wen-Qin Li, Guo-Xing Wan, Yi-Xiao Li, Xiao-Ming Du, Yu-Cong Li, Feng Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Background

SIRT1 expression and Notch1 signaling have been implicated in tumorigenesis in many cancers, but their association with survival in breast cancer has not been determined. The purpose of this study was to assess the possible prognostic value of SIRT1, N1IC, and Snail expression in breast cancer patients.

Methods

Immunohistochemistry was performed to examine the expression of SIRT1, N1IC, and Snail, and the combined expression of SIRT1 and N1IC, using tissue microarrays containing breast cancer tissue and matched adjacent normal breast tissue from 150 breast cancer patients. Survival analysis was carried out using the Kaplan-Meier method. Univariate and multivariate analysis were used to evaluate the prognostic value of SIRT1, N1IC, Snail and combined SIRT1/N1IC expression, in addition to other clinicopathological factors, including grade, lymph node status, disease stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 receptor status in breast carcinoma patients.

Results

SIRT1, N1IC, and Snail were all found to be highly expressed and an inverse correlation between SIRT1 and N1IC in breast cancer tissue. The three markers significantly correlated with lymph node status. Patients with low SIRT1 expression exhibited shorter overall survival (OS) and disease-free survival (DFS), and patients with combined low expression of SIRT1 and high expression of N1IC had the worse OS and DFS. Univariate and multivariate survival analysis revealed that low expression of SIRT1 and SIRT1-low/N1IC-high expression were independent prognostic factors for poor survival.

Conclusions

These results suggest that low expression of SIRT1 or the combined low expression of SIRT1 and high expression of N1IC could be used as indicators of poor prognosis, and may represent novel therapeutic targets in breast cancer.
Appendix
Available only for authorised users
Literature
1.
Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, Koya D: SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem. 2007, 282 (1): 151-158. 10.1074/jbc.M605904200.CrossRefPubMed
2.
Ao N, Liu Y, Feng H, Bian X, Li Z, Gu B, Zhao X, Liu Y: Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by deubiquitinating SIRT1. Cell Physiol Biochem. 2014, 33 (6): 1863-1875. 10.1159/000362964.CrossRefPubMed
3.
Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW, Sylvester KG: SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012, 7: e45119-10.1371/journal.pone.0045119.PubMedCentralCrossRefPubMed
4.
Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001, 107 (2): 149-159. 10.1016/S0092-8674(01)00527-X.CrossRefPubMed
5.
Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001, 107 (2): 137-148. 10.1016/S0092-8674(01)00524-4.CrossRefPubMed
6.
Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005, 123 (3): 437-448. 10.1016/j.cell.2005.08.011.CrossRefPubMed
7.
Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004, 303 (5666): 2011-2015. 10.1126/science.1094637.CrossRefPubMed
8.
Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol. 2011, 42 (2): 204-213. 10.1016/j.humpath.2010.05.023.CrossRefPubMed
9.
Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X: Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012, 29 (5): 3240-3249. 10.1007/s12032-012-0260-6.CrossRefPubMed
10.
Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Ogawa H, Sakurai H, Saiki I, Tobe K: SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep. 2012, 27 (6): 1726-1732.PubMed
11.
Yuan J, Minter-Dykhouse K, Lou ZK: A c-Myc–SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol. 2009, 185 (2): 203-211. 10.1083/jcb.200809167.PubMedCentralCrossRefPubMed
12.
Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L: SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 2013, 3 (4): 1175-1186. 10.1016/j.celrep.2013.03.019.CrossRefPubMed
13.
Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG: Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of P21Waf1/Cip1. Mol Cell Biol. 2006, 26 (7): 2782-2790. 10.1128/MCB.26.7.2782-2790.2006.PubMedCentralCrossRefPubMed
14.
Xie M, Liu M, He C-S: SIRT1 Regulates endothelial notch signaling in lung cancer. Plos One. 2012, 7 (9): 1-11.
15.
Wang XQ, Zhang W, Lui EL, Zhu Y, Lu P, Yu X, Sun J, Yang S, Poon RT, Fan ST: Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer. 2012, 131 (3): 163-172. 10.1002/ijc.27336.CrossRef
16.
Guo Z, Jin X, Jia H: Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of γ-secretase in renal carcinoma. J Exp Clin Cancer Res. 2013, 32 (1): 26-34. 10.1186/1756-9966-32-26.PubMedCentralCrossRefPubMed
17.
Huang J, Song H, Liu B, Yu B, Wang R, Chen L: Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res. 2013, 32 (1): 84-92. 10.1186/1756-9966-32-84.PubMedCentralCrossRefPubMed
18.
Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002, 8 (9): 979-986. 10.1038/nm754.CrossRefPubMed
19.
Wang J, Fu L, Gu F, Ma Y: Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep. 2011, 26 (5): 1295-1303.PubMed
20.
Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, Erşahin Ç, Rajan P: Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol. 2012, 20 (2): 139-145. 10.1177/1066896911427035.CrossRefPubMed
21.
Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65 (18): 8530-8537. 10.1158/0008-5472.CAN-05-1069.CrossRefPubMed
22.
Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, Shah S, Miele L: Notch-1 and notch-4 receptors as prognostic markers in breast cancer. Int J Surg Pathol. 2011, 19 (5): 607-613. 10.1177/1066896910362080.CrossRefPubMed
23.
Mantel CR, Wang RH, Deng C, Broxmeyer HE: Sirt1, notch and stem cell “age asymmetry”. Cell Cycle. 2008, 7 (18): 2821-2825. 10.4161/cc.7.18.6517.CrossRefPubMed
24.
Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, Sato M, Horio Y: Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A. 2008, 105 (40): 15599-15604. 10.1073/pnas.0800612105.PubMedCentralCrossRefPubMed
25.
Sciacca S, Pilato M, Mazzoccoli G, Pazienza V, Vinciguerra M: Anti-correlation between longevity gene SirT1 and Notch signaling in ascending aorta biopsies from patients with bicuspid aortic valve disease. Heart Vessels. 2013, 28 (2): 268-275. 10.1007/s00380-012-0238-5.CrossRefPubMed
26.
Guarani V, Deflorian G, Franco CA, Kruger M, Krüger M, Phng LK, Bentley K, Toussaint L, Dequiedt F, Mostoslavsky R, Schmidt MH, Zimmermann B, Brandes RP, Mione M, Westphal CH, Braun T, Zeiher AM, Gerhardt H, Dimmeler S, Potente M: Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature. 2011, 473 (7346): 234-238. 10.1038/nature09917.PubMedCentralCrossRefPubMed
27.
28.
Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H: Suppression of deacetylase SIRT1 mediates tumor suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res. 2014, 74 (22): 1736-1746. 10.1158/0008-5472.CAN-14-1736.CrossRef
29.
Jethwa P, Naqvi M, Hardy RG, Hotchin NA, Roberts S, Spychal R, Tselepis C: Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol. 2008, 14 (7): 1044-1052. 10.3748/wjg.14.1044.PubMedCentralCrossRefPubMed
30.
Jung W, Hong KD, Jung WY, Lee E, Shin BK, Kim HK, Kim A, Kim BH: SIRT1 Expression is associated with good prognosis in colorectal cancer. Korean J Pathol. 2013, 47 (4): 332-339. 10.4132/KoreanJPathol.2013.47.4.332.PubMedCentralCrossRefPubMed
31.
Kuo SJ, Lin HY, Chien SY, Chen DR: SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein. Oncol Rep. 2013, 30 (1): 125-130.PubMed
32.
Moore RL, Faller DV: SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol. 2013, 216 (3): 273-285. 10.1530/JOE-12-0102.CrossRefPubMed
33.
Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 2009, 15 (13): 4453-4459. 10.1158/1078-0432.CCR-08-3329.CrossRefPubMed
34.
Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 2009, 41 (4): 366-371. 10.1080/00313020902884451.CrossRefPubMed
35.
Choi HN, Bae JS, Jamiyandorj U, Noh SJ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep. 2011, 26 (2): 503-510.PubMed
36.
Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H, Moon WS: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008, 32 (10): 1523-1531. 10.1097/PAS.0b013e31816b6478.CrossRefPubMed
37.
Ben-lin HUA, Xin-ge FU, Feng LI: The compare of Notch1 and JAG1expression in breast cancer and adjacent normal breast tissues. Chin J Clin Exp Pathol. 2009, 25 (2): 127-131. (in Chinese)
38.
Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S: Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res. 2013, 32 (1): 62-70. 10.1186/1756-9966-32-62.PubMedCentralCrossRefPubMed
39.
Kim HS, Jung G: Notch1 increases Snail expression under high reactive oxygen species conditions in hepatocellular carcinoma cells. Free Radic Res. 2014, 48 (7): 806-813. 10.3109/10715762.2014.909595.CrossRefPubMed
40.
Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD: Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011, 9 (12): 1644-1657. 10.1158/1541-7786.MCR-11-0371.CrossRefPubMed
41.
Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ, Katz E: Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clin Exp Metastasis. 2011, 28 (8): 811-818. 10.1007/s10585-011-9412-x.CrossRefPubMed
42.
Sierra RA, Thevenot P, Raber PL, Cui Y, Parsons C, Ochoa AC, Trillo-Tinoco J, Valle LD, Rodriguez PC: Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Cancer Immunol Res. 2014, 2 (8): 800-811. 10.1158/2326-6066.CIR-14-0021.PubMedCentralCrossRefPubMed
43.
Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG: Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med. 2013, 2 (3): 233-242. 10.5966/sctm.2012-0096.PubMedCentralCrossRefPubMed
Metadata
Title
Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer
Authors
Yu-Wen Cao
Wen-Qin Li
Guo-Xing Wan
Yi-Xiao Li
Xiao-Ming Du
Yu-Cong Li
Feng Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-014-0097-2

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue

Research

Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer

Research

Direct to implant breast reconstruction by using SERI®, preliminary report

Research

Store-operated Ca2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation

Research

Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells

Research

The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model

Research

IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits